AspenBio (APPY +4.3%) intends to start a pivotal trial of its AppyScore blood-based appendicitis...

|By:, SA News Editor

AspenBio (APPY +4.3%) intends to start a pivotal trial of its AppyScore blood-based appendicitis test in Q4 after receiving feedback from the FDA. With the diagnostic-product developer's increased focus on AppyScore, four out of nine board members have stepped down. While AspenBio plans to appoint new directors, it also intends to ultimately maintain a smaller board. (PR)